Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: paper man who wrote (418)	6/14/1998 3:54:00 PM
From: OLD JAKE JUSTUS	Read Replies (1) \| Respond to of 4891

You have correctly pointed out that it will take some serious buyers to move ADVR'S stock price upward. In my personal opinion, it should be a $2.00 to $3.00 stock right now. That price is projected because of the heavy potential COMMERCIAL REVENUES sales of Reticulose to the Mercosur States. Commercial Sales, of Reticulose, should begin shortly after a "FREE SALES CERTIFICATE" is issued, to ADVR, by Argentina. Following the conclusion of the Phase 3 testing in Argentina, that country, one of the six Mercousar States, should issue ADVR the Free Sales Certificate. ADVR currently has no FSC from any country in the world. This means that Commercial Sales can begin for the first time ever, for Reticulose! Let's hope it happens, soon! Dr. Shalom Z. Hirschman stated in a public press release on Tuesday, March 31, 1998, in part, the following: "We expect this will result in the approval to market Reticulose, in Argentina, for the treatment of HIV and HPV infected patients and to be followed by the approvals of the other Mercosur States." Unquote. Dr. Hirschman was referring to the ANMAT, the FDA of Argentina, granting an IND Number for final Phase 3 testing of Reticulose on HPV and HIV patients, in Argentina. We have speculated that $1,000,0000,000.00+, or 1 Billion dollars+ of Commercial Sales, of Reticulose, can be generated over the next three years in the Six Mercosur States and another South of the Border country! We estimate that $5,000,000,000.00+ of Commercial Sales, of Reticulcose, can be generated over the next five years from those countries. The Argentina project is very, very important, but there are other developments that could move the price of ADVR stock upward very nicely! We must wait and see! Our day will come! HANG IN THERE AND KEEP THE FAITH!